Company Overview and News

SRAX to Present at the Planet MicroCap Showcase 2018 on April 25 in Las Vegas

2018-04-18 accesswire
LOS ANGELES, CA / ACCESSWIRE / April 18, 2018 / Social Reality, Inc. (NASDAQ: SRAX), a digital marketing and consumer data management and distribution technology platform company, will present at the Planet MicroCap Showcase at 9:30 am PDT on April 25, 2018, and will conduct 1-on-1 meetings on April 26, 2018.
Upvote Downvote


Registration Statement As filed with the Securities and Exchange Commission on April 6, 2018 Registration No. 333-221970
Upvote Downvote

Social Reality's (SRAX) CEO Christopher Miglino on Q4 2017 Results - Earnings Call Transcript

2018-04-02 seekingalpha
Good day. And welcome to the SRAX Fourth Quarter and Full Year 2017 Results Conference Call. Today’s conference is being recorded. At this time, I would like to turn the conference over to Kirsten Chapman of LHA Investor Relations. Please go ahead, Ma’am.
Upvote Downvote

SCRI / Social Reality Inc. ANNUAL REPORT (Annual Report)

Upvote Downvote

SCRI / Social Reality Inc. CURRENT REPORT (Current Report)

Current Report UNITED STATES
Upvote Downvote

Short Sellers Look Quite Aggressive Against Bitcoin, Cryptocurrency and Blockchain Stocks

2018-03-12 247wallst
In the world of bitcoin, blockchain and cryptocurrency trading, there has been a story that went from rags to riches and back to rags in a pretty short time. The underlying technology is of course set to remain in place. Still, many investors and speculators think that bitcoin itself and the subsequent cryptocurrencies are just the next bubble.
Upvote Downvote

BRIEF-Social Reality Says ‍Alpha Release Of Blockchain Technology Big Platform To A Limited, By Invitation Only Group Of Users​

2018-03-12 reuters
Upvote Downvote

SRAX to Present at the Inaugural LD Micro Virtual Conference

2018-03-06 accesswire
LOS ANGELES, CA / ACCESSWIRE / March 6, 2018 / Social Reality, Inc. (NASDAQ: SRAX), a digital marketing and data management platform delivering the tools to reach and reveal valuable audiences, announced it will participate in the inaugural LD Micro Virtual Conference on Thursday, March 8 at 7:00 AM PST /10:00 AM EST. Chairman and CEO Christopher Miglino will deliver the presentation and answer questions from investors.
Upvote Downvote

Top 5 Trends I Am Following In 2018

2018-03-02 seekingalpha
This article first appeared on Trend Investing on January 22, 2018; therefore all data is as of that date.
Upvote Downvote

Equity Commonwealth upgraded to buy from hold at Stifel Nicolaus

2018-02-16 marketwatch
A venture of one of Chicago’s most active real-estate developers and JP Morgan Asset Management are in advanced talks to buy Groupon Inc.’s headquarters for about $520 million from Sam Zell’s Equity Commonwealth, according to people familiar with the matter.
Upvote Downvote


Amended Registration Statement   As filed with the Securities and Exchange Commission on February 7, 2018 Registration No. 333-221970     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3/A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Social Reality, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 45-2925231 (I.
Upvote Downvote

SeeThruEquity Issues Update on Social Reality, Inc. (SRAX) with Target Price of $8.40

2018-02-07 accesswire
NEW YORK, NY / ACCESSWIRE / February 7, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on Social Reality, Inc. (NASDAQ: SRAX) and updated its target price to $8.40.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 83362P300